Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 11/20 | 0.59 |
| ▸ | CNR2 | P34972 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | BCR | P11274 | 2/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14526737 | 0.90 | AKT3 (0.48) | AKT3DYRK1ADYRK1B | |
| SCHEMBL12509343 | 0.90 | AKT3 (0.50) | AKT3ABL1BCRCDK2 | |
| SCHEMBL12423662 | 0.89 | AKT3 (0.61) | AKT3CNR2DYRK1ADYRK1BABL1 | |
| SCHEMBL12423316 | 0.88 | AKT3 (0.60) | AKT3CNR2DYRK1ADYRK1BABL1 | |
| SCHEMBL12423663 | 0.87 | AKT3 (0.60) | AKT3CNR2DYRK1ADYRK1BABL1 | |
| SCHEMBL4927821 | 0.83 | AKT3 (0.61) | AKT3CNR2DYRK1ADYRK1BABL1 | |
| SCHEMBL4991070 | 0.83 | AKT3 (0.82) | AKT3PRKCA | |
| SCHEMBL14619443 | 0.82 | CDK2 (0.50) | AKT3CDK2 | |
| SCHEMBL2196849 | 0.82 | AKT3 (0.55) | AKT3CNR2 | |
| SCHEMBL3097637 | 0.82 | AKT3 (0.54) | AKT3CNR2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977481-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | ARNOLD WILLIAM D | 2010-12-02 | — | — | US | disclosed |
| US-7803806-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803806-B2 | Pyrimidinyl-thiophene kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| WO-2007053776-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305128-A1 | Pyrimidinyl-Thiophene Kinase Modulators | MAP3K20, MAP3K6, MAP4K2 | AKT3 340/4885CNR2 2660/4885DYRK1A 402/4885 |
| US-20070117800-A1 | PYRIMIDINYL-THIOPHENE KINASE MODULATORS | MAP3K20, MAP3K6, MAP4K2 | AKT3 340/4885CNR2 2660/4885DYRK1A 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.